A preliminary study of resting brain metabolism in treatment-resistant depression before and after treatment with olanzapine-fluoxetine combination

Abstract

Treatment-resistant depression (TRD) occurs in many patients and causes high morbidity and mortality. Because TRD subjects are particularly difficult to study especially longitudinally, biological data remain very limited. In a preliminary study to judge feasibility and power, 25 TRD patients were referred from specialty psychiatric practices. All were severely and chronically depressed and mostly had comorbid psychiatric disorders as is typical in TRD. Nine patients were able to complete all required components of the protocol that included diagnostic interview; rating scales; clinical magnetic resonance imaging; medication washout; treatment with maximally tolerated olanzapine-fluoxetine combination for 8 weeks; and pre-and post-treatment fluorodeoxyglucose positron emission tomography. This drug combination is an accepted standard of treatment for TRD. Dropouts arose from worsening depression, insomnia, and anxiety. One patient remitted; three responded. A priori regions of interest included the amygdala and subgenual cingulate cortex (sgACC; Brodmann area BA25). Responders showed decreased metabolism with treatment in the right amygdala that correlated with clinical response; no significant changes in BA25; better response to treatment the higher the baseline BA25 metabolism; and decreased right ventromedial prefrontal metabolism (VMPFC; broader than BA25) with treatment which did not correlate with depression scores. The baseline metabolism of all individuals showed heterogeneous patterns when compared to a normative metabolic database. Although preliminary given the sample size, this study highlights several issues important for future work: marked dropout rate in this study design; need for large sample size for adequate power; baseline metabolic heterogeneity of TRD requiring careful subject characterization for future studies of interventions; relationship of amygdala activity decreases with response; and the relationship between baseline sgACC and VMPFC activity with response. Successful treatment of

Inflammation and Treatment-Resistant Depression from Clinical to Animal Study: A Possible Link?

“…The CUMS protocol is an established translationally relevant model for inducing behavioral symptoms commonly associated with clinical depression in rodents, such as anhedonia, altered grooming behavior and learned helplessness [ 22 ]. We created a chronic unpredictable mild stressful environment using stress and diet to induce antidepressant resistance.…”

The utility of PET imaging in depression

“…Also, when depressed patients on SSRI medications start to feel better, there is often an increase in the number of specific receptors, called 5-HT 2A , in the frontal cortex of the brain ( 65 , 66 ). Furthermore, one [ 18 F]FDG PET study showed olanzapine (an atypical antipsychotic) and fluoxetine (an SSRI) combination therapy yielded metabolic changes in the brain in patients with therapy-resistant depression, resembling those observed in individuals with therapy-responsive major depression ( 67 ).…”

Targeting Inflammatory-Mitochondrial Response in Major Depression: Current Evidence and Further Challenges

“…Another recent FDA-approved drug for treating TRD is Symbyax, which combines olanzapine (an atypical antipsychotic) and fluoxetine (a selective serotonin reuptake inhibitor) [116,117]. A recent study of 25 patients treated with Symbyax for 8 weeks showed a decline in amygdala activity and right ventromedial prefrontal metabolism, and these events were correlated with improvement in depression after the intervention [118].…”